Why Moderna Stock Took a 6% Tumble Today
Moderna's (NASDAQ: MRNA) bread and butter at the moment is Spikevax, its coronavirus vaccine. However, with cases and deaths dropping notably in many (although not all) jurisdictions, some investors are doubtful that the company is worth its rather lofty valuations.
This concern came to the surface on Tuesday. News that a pair of large and important customers have declined to exercise options for more Spikevax doses sent Moderna shares down by slightly more than 6% on the day.
Image source: Getty Images.
Source Fool.com
